“These results indicate that cannabidiol represents a potential protective agent against doxorubicin cardiac injury”
Another day, another new study! This one published in the journal Environmental Toxicology and Pharmacology noted that everyone’s newest friend, the CBD cannabinoid – a.k.a cannabidiol – and the ‘poster cannabinoid’ for medical marijuana, could very well protect the heart from the dangerous side effects associated with doxorubicin (commonly known as Doxil). Doxil is part of a group of chemotherapy drugs known as anthracycline antibiotics, and has been shown to slow or even halt the growth of aggressive cancer cells.
Within the recent study, the “potential protective effect of cannabidiol, the major non-psychotropic Cannabis constituent, was investigated against doxorubicin cardiotoxicity in rats.”
no images were found
Scientist discovered when lab rats were administered small doses of the CBD cannabinoid, in conjunction with a standard doses of Doxil, there was no detectable heart issues associated with the doxorubicin. Conversely, the lab rats that were exposed to doxorubicin, but not given any CBD cannabinoids, showed signs of notable harm done by the drug.
“The potential protective effect of cannabidiol, the major non-psychotropic Cannabis constituent, was investigated against doxorubicin cardiotoxicity in rats. Cardiotoxicity was induced by six equal doses of doxorubicin (2.5 mg kg−1 i.p., each) given at 48 h intervals over two weeks to achieve a total dose of 15 mg kg−1. Cannabidiol treatment (5 mg kg−1/day, i.p.) was started on the same day of doxorubicin administration and continued for four weeks. Cannabidiol significantly reduced the elevations of serum creatine kinase-MB and troponin T, and cardiac malondialdehyde, tumor necrosis factor-α, nitric oxide and calcium ion levels, and attenuated the decreases in cardiac reduced glutathione, selenium and zinc ions. Histopathological examination showed that cannabidiol ameliorated doxorubicin-induced cardiac injury. Immunohistochemical analysis revealed that cannabidiol significantly reduced the expression of inducible nitric oxide synthase, nuclear factor-κB, Fas ligand and caspase-3, and increased the expression of survivin in cardiac tissue of doxorubicin-treated rats. These results indicate that cannabidiol represents a potential protective agent against doxorubicin cardiac injury.”